Swedbank AB Grows Stake in Boston Scientific Corporation $BSX

Key Points

• Swedbank AB increased its stake in Boston Scientific by 21.7%, buying 611,167 shares to hold 3,429,844 shares (0.23% of the company) worth about $327.0 million, and institutional investors now own roughly 89.07% of BSX.
• Boston Scientific beat Q1 expectations with $0.80 EPS (consensus $0.79) and $5.20 billion in revenue (up 11.6% YoY), and issued Q2 2026 guidance of $0.820–0.840 EPS and FY 2026 guidance of $3.340–3.410 EPS.
• BSX trades with a market cap of about $83.2 billion and a P/E of 23.42; analysts maintain a consensus rating of "Moderate Buy" with an average price target of $93.91.

Swedbank AB raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 21.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,429,844 shares of the medical equipment provider's stock after purchasing an additional 611,167 shares during the period. Swedbank AB owned 0.23% of Boston Scientific worth $327,036,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Murphy & Mullick Capital Management Corp raised its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter valued at about $26,000. United Community Bank raised its position in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 147 shares during the last quarter. Colonial Trust Co SC boosted its stake in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank boosted its stake in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 142 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Down 1.5%

BSX stock opened at $55.98 on Wednesday. The company has a market capitalization of $83.20 billion, a P/E ratio of 23.42, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62. Boston Scientific Corporation has a 12 month low of $55.88 and a 12 month high of $109.50. The firm's fifty day simple moving average is $66.69 and its 200-day simple moving average is $84.28. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. During the same quarter last year, the company posted $0.75 earnings per share. The firm's revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research analyst reports. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. Sanford C. Bernstein reissued an "outperform" rating and issued a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. Wells Fargo & Company reduced their target price on Boston Scientific from $94.00 to $75.00 and set an "overweight" rating for the company in a research note on Thursday, April 23rd. Argus raised Boston Scientific to a "strong-buy" rating in a research report on Thursday, February 26th. Finally, Royal Bank Of Canada dropped their price target on Boston Scientific from $105.00 to $100.00 and set an "outperform" rating on the stock in a research note on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $93.91.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.